1. Home
  2. Press release
Mar 19, 2020 15:15 JST

Source: Eisai

Eisai: All-case Surveillance Condition for Approval of "Actonel 17.5 mg tablets" for Treatment of Paget's Disease of Bone Cleared in Japan


TOKYO, Mar 19, 2020 - (JCN Newswire) - EA Pharma Co., Ltd. and its parent company Eisai Co., Ltd. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has given notification of the results of reexamination to the effect that the "all-case surveillance" specified drug use-results survey condition required for the approval of "Actonel 17.5 mg tablets" (risedronate sodium hydrate) indicated for the treatment of Paget's disease of bone has been lifted.

In July 2008, MHLW approved the indication for treatment of "Paget's disease of bone" for "Actonel 17.5 mg tablets" with the following conditions for approval: "Because of the very limited number of subjects treated in the Japanese clinical trials, the applicant is required to conduct all-case drug use-results survey until data from a certain number of patients are accumulated after market launch, in order to identify the background information of patients treated with the product and collect safety and efficacy data on the product in the early post-marketing period, and thereby take necessary measures to ensure proper use of the product."

Based on the safety data in 307 patients and efficacy data in 276 patients submitted to MHLW as the results of analyses of all-case surveillance, MHLW has concluded that the all-case surveillance was conducted properly and the necessary measures to ensure proper use of the product were being taken sufficiently to lift the condition.

EA Pharma Co., Ltd. and Eisai Co., Ltd. continually strive to promote proper use of the product and provide timely additional information of the product to increase benefits to patients and their families.


About Eisai
Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com


Contact:
EA Pharma Co., Ltd. 
Corporate Planning Dept. 
TEL: +81(0)3-6280-9802

Eisai Co., Ltd. 
Public Relations Dept. 
TEL: +81(0)3-3817-5120
Source: Eisai
Sectors: HealthCare

Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai: Brain Performance (Brain-Health) Self-Check Tool "NouKNOW" to be Used in Beauty Salons
June 04 2020 10:43 JST
 
Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia
June 02 2020 10:05 JST
 
AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody
May 29 2020 14:54 JST
 
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials
May 29 2020 10:31 JST
 
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules
May 18 2020 12:33 JST
 
Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting
May 14 2020 08:22 JST
 
Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine
April 27 2020 16:26 JST
 
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China
April 01 2020 15:23 JST
 
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)
March 26 2020 16:01 JST
 
Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20
March 25 2020 08:38 JST
 
More Press release >>

Latest Press Release


TOYOTA GAZOO Racing to Make Virtual Le Mans Debut
Jun 05, 2020 17:34 JST

Toyota Mobility Foundation to Expand Provision of Connected and Sanitized Mobility Services to support Healthcare in Indonesia in Support of the Fight against COVID-19
Jun 05, 2020 17:22 JST

Six Companies Establish R&D Joint Venture for Commercial Vehicle Fuel Cell Systems for the Creation of a Hydrogen-based Society in China
Jun 05, 2020 17:01 JST

Singapore's LABMED shipped over 20 million masks to meet global demand
Jun 04, 2020 22:00 JST

Eisai: Brain Performance (Brain-Health) Self-Check Tool "NouKNOW" to be Used in Beauty Salons
Jun 04, 2020 11:43 JST

NEC's Netcracker 2020 Puts Service Providers at the Center of the Digital Economy
Jun 04, 2020 09:15 JST

Rakuten Mobile and NEC Agree to Jointly Develop Containerized Standalone 5G Core Network
Jun 03, 2020 10:34 JST

The Toyota Mobility Foundation and Partners Establish Digital Platform to Help Support People and Industry in Rural Germany
Jun 03, 2020 09:05 JST

Mitsubishi Corporation and NTT complete investment in HERE Technologies
Jun 02, 2020 14:54 JST

Toyota Announces its Line-up for the New GR Yaris in Japan
Jun 02, 2020 13:35 JST

Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia
Jun 02, 2020 11:05 JST

MHI RJ Aviation Group Launches as Mitsubishi Heavy Industries Ltd. Closes Acquisition of CRJ Series Program From Bombardier Inc.
Jun 02, 2020 10:23 JST

LEXUS previews the New IS
Jun 02, 2020 09:12 JST

DENSO and Certhon Establish DENSO AgriTech Solutions
Jun 01, 2020 12:48 JST

Fujitsu Signs Partnership Agreement with Scaled Agile, Inc., Driving Large-Scale Agile for Digital Transformation
Jun 01, 2020 12:01 JST

AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody
May 29, 2020 15:54 JST

Sharp Releases Notice of Corporate Spin-Off of the Display Device Business Division
May 29, 2020 15:47 JST

DENSO Announces Changes in the Areas of Responsibility of Senior Executive Officers and Executive Officers
May 29, 2020 12:05 JST

Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials
May 29, 2020 11:31 JST

Hitachi Announces Change in the Effective Date for Company Split and Closing Date of Share Transfer
May 28, 2020 19:18 JST
 More Latest Release >>